Qiming Venture Partners-backed precision proteomics leader Alamar Biosciences debuts on Nasdaq
Qiming Venture Partners led Alamar Biosciences' Series A round in 2020, and continued to back the company in its Series B and C rounds.
Swipe Left for the English Version
On April 17, 2026, Beijing Time, Alamar Biosciences — a Qiming Venture Partners portfolio company and leader in precision proteomics — successfully listed on the NASDAQ Stock Exchange, marking Qiming's fifth IPO since the start of the year. Alamar Biosciences (NASDAQ: ALMR) priced its shares at $17 and opened at $22.60, giving it a market cap of approximately $1.5 billion.
In 2020, Qiming Venture Partners led Alamar Biosciences' Series A round and continued to back the company through its Series B and C. Prior to the IPO, Qiming held roughly a 19.2% stake in Alamar, making it one of the company's most significant institutional investors.
Founded in 2018, Alamar Biosciences is dedicated to developing and commercializing proteomics technologies, with the goal of establishing the gold standard for protein detection and analysis. The company's proprietary NULISA™ technology overcomes the design limitations of existing proteomics tools, delivering ultra-high sensitivity, high specificity, flexible multiplex protein detection, broad dynamic range, and seamless automation — enabling the detection of protein biomarkers at extremely low concentrations and filling critical gaps left by other protein detection methods.
In addition, Alamar's self-developed ARGO™ HT fully automated, high-throughput system enables a "sample-to-answer" workflow, driving rapid market penetration. By the end of 2025, cumulative ARGO™ HT installations exceeded 100 units across more than 300 customers in 25 countries. Since the platform's commercial launch, over 100 scientific papers have been published based on its technologies and products.
William Hu, Managing Partner at Qiming Venture Partners (left), with Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences (right)
"Congratulations to Alamar on its successful listing," said William Hu, Managing Partner at Qiming Venture Partners. "We firmly believe that ultra-high-sensitivity proteomics will fundamentally reshape the future of early disease screening and precision diagnostics. It was this conviction that led us to invest in Alamar at an early stage, and we have been proud to support and accompany the company's growth ever since. We look forward to Alamar leveraging its world-leading proteomics platform to deliver earlier, more accurate, and more accessible precision diagnostics — bringing cutting-edge medical technology into clinical practice to benefit patients worldwide and create lasting value for global healthcare systems."
Past Coverage
Morning Star | Alamar Biosciences Closes $80 Million Series B, Qiming Venture Partners Continues Investment | Bilingual Morning Star | Alamar Officially Expands into Asia-Pacific, Hong Kong Center for Neurodegenerative Diseases Achieves First ARGO™ HT Installation in Region | Bilingual Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol. 12, 2026.4.7
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in exceptional early- and growth-stage companies in technology and healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Harpoon Therapeutics, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.